Apex Biotechnology Corp. (TPE:1733)
Taiwan · Delayed Price · Currency is TWD 31.75
-0.25 (-0.78%)
Jul 30, 2026, 1:30 PM CST
Apex Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,198 | 3,043 | 3,009 | 4,028 | 2,554 | 2,599 | |
Market Cap Growth | 14.49% | 1.16% | -25.31% | 57.73% | -1.73% | 10.38% |
Enterprise Value | 2,640 | 2,594 | 2,667 | 3,842 | 2,337 | 2,292 |
Last Close Price | 32.00 | 29.13 | 27.68 | 35.90 | 21.66 | 20.98 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.67 | 18.68 | 23.50 | 34.79 | 14.05 | 12.85 |
Forward PE | - | 13.11 | 13.11 | 13.11 | 13.11 | 13.11 |
PS Ratio | 1.68 | 1.57 | 1.62 | 2.40 | 1.14 | 1.22 |
PB Ratio | 1.75 | 1.63 | 1.65 | 2.24 | 1.41 | 1.48 |
P/TBV Ratio | 1.79 | 1.66 | 1.69 | 2.30 | 1.46 | 1.58 |
P/FCF Ratio | 17.02 | 21.01 | 10.01 | 19.32 | - | 16.95 |
P/OCF Ratio | 15.35 | 19.01 | 9.15 | 17.48 | 95.95 | 14.45 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.39 | 1.33 | 1.44 | 2.29 | 1.04 | 1.08 |
EV/EBITDA Ratio | 11.46 | 13.59 | 14.65 | 18.60 | 8.99 | 7.86 |
EV/EBIT Ratio | 15.37 | 18.44 | 20.76 | 27.11 | 13.24 | 11.18 |
EV/FCF Ratio | 14.05 | 17.91 | 8.88 | 18.43 | - | 14.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.07 | 0.09 | 0.10 | 0.16 |
Debt / EBITDA Ratio | 0.47 | 0.55 | 0.64 | 0.71 | 0.67 | 0.95 |
Debt / FCF Ratio | 0.58 | 0.76 | 0.41 | 0.74 | - | 1.86 |
Net Debt / Equity Ratio | -0.31 | -0.29 | -0.26 | -0.16 | -0.12 | -0.19 |
Net Debt / EBITDA Ratio | -2.53 | -2.80 | -2.61 | -1.41 | -0.83 | -1.17 |
Net Debt / FCF Ratio | -2.98 | -3.69 | -1.58 | -1.39 | 21.76 | -2.22 |
Asset Turnover | 0.77 | 0.80 | 0.79 | 0.70 | 0.87 | 0.80 |
Inventory Turnover | 2.33 | 2.30 | 1.89 | 1.54 | 2.44 | 2.75 |
Quick Ratio | 2.10 | 2.53 | 2.00 | 1.93 | 1.57 | 1.42 |
Current Ratio | 3.14 | 3.87 | 3.44 | 3.93 | 2.90 | 2.24 |
Return on Equity (ROE) | 10.16% | 8.82% | 7.07% | 6.40% | 10.16% | 11.90% |
Return on Assets (ROA) | 4.35% | 3.64% | 3.40% | 3.68% | 4.26% | 4.81% |
Return on Invested Capital (ROIC) | 12.27% | 9.00% | 7.53% | 7.49% | 10.65% | 14.91% |
Return on Capital Employed (ROCE) | 8.90% | 7.10% | 6.60% | 7.40% | 9.10% | 10.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.69% | 5.35% | 4.25% | 2.87% | 7.12% | 7.78% |
FCF Yield | 5.88% | 4.76% | 9.99% | 5.18% | -0.39% | 5.90% |
Dividend Yield | 4.10% | 4.46% | 4.34% | 3.06% | 6.46% | 6.20% |
Payout Ratio | 65.85% | 73.63% | 85.90% | 120.86% | 71.48% | 54.06% |
Buyback Yield / Dilution | -0.19% | -0.15% | -0.08% | 0.34% | 4.70% | 6.53% |
Total Shareholder Return | 3.91% | 4.31% | 4.26% | 3.41% | 11.16% | 12.73% |